Jun 10, 2024 · We compared relapse incidence (RI) post-unrelated transplantation with post-transplant cyclophosphamide (PTCy) versus no PTCy graft-versus-host disease (GVHD) ...
We compared relapse incidence (RI) post-unrelated transplantation with post-transplant cyclophosphamide (PTCy) versus no PTCy graft-versus-host disease (GVHD) ...
Relapse incidence post unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide (PTCy) versus conventional anti-graft versus host ...
May 20, 2024 · versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute ...
Oct 2, 2024 · We compared relapse incidence (RI) post‐unrelated transplantation with post‐transplant cyclophosphamide (PTCy) versus no PTCy graft‐versus‐host ...
The study aim was to compare PTCy with TAC or cyclosporine A (CSA) and MMF (PTCy/TAC or CSA & MMF) to ATG combined with TAC and MTX (ATG/TAC/MTX) in acute
Incidence of GVHD and NRM were significantly lower with PTCy resulting in significantly better GRFS with PTCy compared to no PTCy anti-GVHD prophylaxis.
Missing: conventional | Show results with:conventional
Aug 31, 2024 · Our results suggest that transplantation outcomes are better with UD 9/10 with PTCy-based GVHD prophylaxis than with dCBT for AML patients in CR1.
Missing: allogeneic conventional anti- behalf
Jul 3, 2024 · Post-transplant cyclophosphamide and tacrolimus-mycophenolate mofetil combination prevents graft-versus-host disease in allogeneic peripheral ...
People also ask
How common is relapse after stem cell transplant?
Relapse of the original malignancy after SCT now remains the most frequent cause of treatment failure and mortality. Approximately 40–45% of recipients of HLA-identical siblings and approximately 35% of recipients of unrelated donor transplants will relapse with their original malignancy (Figure 1) [1].
How often does AML relapse after bone marrow transplant?
Relapse of AML after HSCT affects about 30–40% of HSCT recipients [1,2,3]. The prognosis of relapse of AML after HSCT is poor with a 3-year survival rate of around 20–30% [1,2].
What is the prognosis for AML patients after stem cell transplant?
The Center of International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Donor Program (NMPD) have been reported 65% survival rates in AML patients after stem cell transplantation, while the 5-year survival rate of adult subjects with AML without allo-SCT is approximately 24% 16-18.
What happens if leukemia comes back after stem cell transplant?
Donor lymphocyte infusion (DLI) can be used if you've had a stem cell transplant but a relapse is detected, or the amount of donor cells in your bone marrow is falling. Donor lymphocyte infusion can also be used if you are in remission but have a positive MRD test.
Apr 11, 2023 · Post-transplant cyclophosphamide (PTCy)-based platforms abated the risk of GVHD thereby overcoming the negative effects of HLA-mismatching on survival.